BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23958463)

  • 1. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
    Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.
    Yang J; Yu H; Shen M; Wei W; Xia L; Zhao P
    Cancer Sci; 2014 Feb; 105(2):219-27. PubMed ID: 24262005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.
    Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN
    Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
    Liu Y; Liu R; Fu P; Du F; Hong Y; Yao M; Zhang X; Zheng S
    Cell Physiol Biochem; 2015; 36(6):2494-503. PubMed ID: 26279450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells.
    Fang L; Gao L; Xie L; Xiao G
    Oncol Rep; 2018 Mar; 39(3):1283-1291. PubMed ID: 29286162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.
    Wang X; Jiang R; Cui EH; Feng WM; Guo HH; Gu DH; Tang CW; Xue T; Bao Y
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1244-50. PubMed ID: 27097942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells.
    Zhou QY; Tu CY; Shao CX; Wang WK; Zhu JD; Cai Y; Mao JY; Chen W
    Am J Transl Res; 2017; 9(5):2608-2617. PubMed ID: 28560008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
    Tang DJ; Dong SS; Ma NF; Xie D; Chen L; Fu L; Lau SH; Li Y; Li Y; Guan XY
    Hepatology; 2010 Apr; 51(4):1255-63. PubMed ID: 20112425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
    Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
    Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.
    Liu Y; Xue F; Zhang Y; Lei P; Wang Z; Zhu Z; Sun K
    Anticancer Drugs; 2017 Nov; 28(10):1097-1105. PubMed ID: 28885268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
    Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
    BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cells.
    Fang L; Gao L; Xie L; Xiao G
    J Cancer; 2018; 9(19):3479-3488. PubMed ID: 30310504
    [No Abstract]   [Full Text] [Related]  

  • 15. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition.
    Bao Y; Zhang Y; Lu Y; Guo H; Dong Z; Chen Q; Zhang X; Shen W; Chen W; Wang X
    Int J Biol Sci; 2020; 16(5):827-837. PubMed ID: 32071552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.
    Yao M; Hong Y; Liu Y; Chen W; Wang W
    Exp Ther Med; 2017 Sep; 14(3):2101-2107. PubMed ID: 28962130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma.
    Xue F; Liu Y; Chu H; Wen Y; Yan L; Tang Q; Xiao E; Zhang D; Zhang H
    Am J Transl Res; 2016; 8(11):4670-4681. PubMed ID: 27904670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
    Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
    Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
    Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EIF5A2 is a novel chemoresistance gene in breast cancer.
    Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
    Breast Cancer; 2015 Nov; 22(6):602-7. PubMed ID: 24638963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.